Omada for Diabetes Program Achieves Key Clinical Outcomes
Summary
Those with a baseline A1C below 7 percent maintained their A1C at goal, as measured by treatment guidelines published by the American Diabetes Association. “Omada’s approach to digital care means delivering meaningful results in real-world settings,” said company Co-Founder and CEO Sean Duffy. Omada will publish a white paper in the coming weeks with additional details on the early cohort results. Reporting on blood value reductions in hemoglobin A1c is an example of Omada’s commitment to delivering outcomes that meet clinical standards, and customers can trust. Peer-reviewed literature indicates that for every one point reduction in A1C: Employers and health plans can learn more about Omada’s pioneering approach to digital care at one of two upcoming virtual events: In October, Omada announced a partnership with Abbott to integrate the revolutionary FreeStyle Libre System, a continuous glucose monitoring (CGM) technology, into the Omada for Diabetes Program.
Classifications
AskAI Classifications
LabelsLinked Companies
